Cerezyme® (imiglucerase)

Cerezyme (imiglucerase) is covered only for Type 1 Gaucher disease (other Gaucher types or non‑Gaucher diagnoses are not covered). Coverage requires documentation of deficient β‑glucocerebrosidase activity in leukocytes or fibroblasts OR molecular genetic confirmation of a GBA mutation, prescription by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or lysosomal storage disorder specialist, a treatment plan consistent with 60 U/kg IV every other week, and is approved for up to 1 year.

"Cerezyme is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.